LC
ARQT icon

Lindbrook Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Lindbrook Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$6.13K Buy
392
+9
+2% +$127 ﹤0.01% 1871
2024
Q4 		$5.33K Buy
383
+26
+7% +$285 ﹤0.01% 1956
2024
Q3 		$3.32K Hold
357
– – ﹤0.01% 2174
2024
Q2 		$3.32K Sell
357
-125
-26% -$1.13K ﹤0.01% 2176
2024
Q1 		$4.78K Buy
+482
New +$3.6K ﹤0.01% 1912
2023
Q4 		– Sell
-140
Closed -$743 – 2696
2023
Q3 		$743 Buy
140
+56
+67% +$476 ﹤0.01% 2436
2023
Q2 		$801 Buy
+84
New +$932 ﹤0.01% 2414
2022
Q4 		– Sell
-138
Closed -$3K – 2833
2022
Q3 		$3K Buy
138
+12
+10% +$272 ﹤0.01% 1834
2022
Q2 		$3K Buy
126
+10
+9% +$205 ﹤0.01% 1743
2022
Q1 		$2K Buy
+116
New +$1.96K ﹤0.01% 1934

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's ARQT Position: Q1 2025 in Review

Lindbrook Capital increased its Arcutis Biotherapeutics (ARQT) stake by 2.3% in Q1 2025, buying an estimated $127 and bringing the position to 392 shares worth $6.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Lindbrook Capital first reported a position in ARQT in Q1 2022 and has held it in 10 quarters since. 241 funds tracked by Wall St. Rank hold ARQT as of Q1 2025.

  • Lindbrook Capital held 392 shares of Arcutis Biotherapeutics worth $6.13K as of Q1 2025.
  • Lindbrook Capital bought 9 Arcutis Biotherapeutics shares in Q1 2025, an estimated $127.
  • Arcutis Biotherapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1871 holding.
  • Lindbrook Capital first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 10 quarters since.
  • 241 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.